<?xml version="1.0" encoding="UTF-8"?>
<p>There are data on the clinical trials of the foreign drug analogue Polyadenur (PolyA:PolyU with a molecular mass ranged from 250 kDa to 1500 kDa). It has been developed by Beaufour Ipsen (France) together with Hemispherx Biopharma (USA), for using as a component of complex therapy (in combination with IFN-α) of hepatitis B and C, and also for treatment of breast cancer [
 <xref ref-type="bibr" rid="CR63">63</xref>–
 <xref ref-type="bibr" rid="CR65">65</xref>].
</p>
